Steep Hill Labs
Global Leader in Cannabis Testing and Analytics
Steep Hill Labs is the world’s leading cannabis science and technology company with extensive expertise in lab testing, remote testing, genetics, R&D, and the licensing of intellectual property to strategic partners across the globe. Steep Hill’s foundation was built on testing and analyzing medical and recreational marijuana to ensure compliance with public safety standards.
Leading the Science of Cannabis
Steep Hill Labs pioneered the first medical cannabis potency and microbiological contaminants testing methodology for use in California in 2008 – the first state to legalize medical cannabis. Steep Hill is expanding throughout the United States, and globally. The company has since developed a variety of revolutionary cannabis testing products, including QuantaCann™, QuantaCann2™ and GenKit™. Steep Hill provides expert consulting services to many states, countries and municipalities, and the company is developing proprietary genetic testing, mapping and trademark protection services.
Steep Hill is an innovative research and development
lab that generates highly-differentiated products
Protecting public health through the development of infrastructure and analytical services for legally-authorized cultivators, processors, distributors, retailers, and regulators of cannabis.
Expanding Geographic Reach with Steep Hill Lab Locations
Steep Hill’s innovative hub-and-spoke approach to providing remote testing was among the driving factors in the decision to work with Alaska. Central to this solution is a proprietary system that can provide testing in Alaskan communities that are not on the road system. In addition, this agreement will enable Steep Hill to bring testing capabilities to Alaska that are far beyond those that are currently available here, such as genetics testing and strain identification.
Steep Hill Arkansas is proud to serve the patients of the Natural State by providing rigorous quality-standard testing of contaminants to ensure pure and safe medical cannabis. Co-owned by two Arkansans who share a strong belief in cannabis as a medicine with many benefits, we are pleased to bring the industry’s leading cannabis science company to Arkansas.
The Steep Hill laboratory in Oakland, California was the first testing and research facility. Located at the heart of the cannabis legalization movement and serving the largest population of legal cannabis consumers, Steep Hill California provides extensive cannabis testing services to any cultivators, processors, dispensaries, collectives and Proposition 215-compliant medical cannabis patients with a valid recommendation and state-issued picture ID.
Steep Hill Hawaii is a full service laboratory located in the heart of Honolulu, Hawaii. It’s Hawaii’s 1st ISO/IEC 17025:2005 accredited lab in the state and provide testing for local cardholders. Steep Hill is also certified by the Hawaii Dept of Health to conduct full compliance testing for local dispensaries.
Steep Hill Los Angeles serves the Southern California market with our Express Potency service as well as acts as a sample drop-off location for the Berkeley lab.
The entry of Steep Hill Maryland marks a new era in cannabis safety. The Maryland team is composed of laboratory specialists, health care experts, and physicians, including board-certified pathologists and gastroenterologists who have been involved in patient care and diagnostic medicine for decades.
Steep Hill was awarded the first testing license by the NW Department of Public Health. New Mexico is officially the fifth laboratory to open that follows Steep Hill standards and methods of procedure.
Highly respected pain and addiction physician Dr. Carl Balog plans to open Steep Hill Oregon as a full service medical and adult use cannabis quality assurance laboratory and research facility in Portland, Oregon, bringing Steep Hill’s proprietary advanced scientific tools and methodology to the state.
The Steep Hill laboratory in Seattle, Washington was the third testing and research facility. Steep Hill is a fully licensed I-502 testing facility, with state of the art equipment, and the best testing methodology in the industry.
Seasoned Executive and Scientific Team
President and CEO
Mr. Keller leads the strategic vision and exponential growth of the company, implementing the systems that have strengthened the company’s financial results while building effective and cohesive teams. Originally joining Steep Hill as an investor, Mr. Keller recognized that experience in growing his previous software company could be leveraged to create a competitive advantage by building the Steep Hill myLab™ software solution. His keen intuition and clarity for entrepreneurship, combined with his desire to unlock the potential in every human makes him a truly inspirational leader.
Brian Brandley, Ph.D., MBA
Chief Lab Officer
Dr. Brandley oversees the daily operations of capacity planning, quality control, and laboratory management, as well as, the strategic planning of capacity, equipment and personnel. Dr. Brandley has garnered 30 years of experience directing cross-disciplinary teams of chemists, biologists and business units. He led research organizations in analytical, preclinical, and GMP operations at multiple pharmaceutical and biotech companies where he directed R&D teams, researched INDs & NDAs, managing validations, specifications, stability protocols & intellectual property.
Jane Wright-Mitchell, PhmD, JD
Chief Legal Officer
Ms. Wright-Mitchell advises Steep Hill on all legal and compliance matters. She manages legal risk, including protecting Steep Hill’s intellectual property, regulatory, human resource and financial business interests, and manages outside legal counsel. She joins the company with a wealth of legal management experience having worked for multiple publicly-traded pharmaceutical companies. She holds a BS in Biological Sciences from Clemson University, a Pharm.D. from the University of Illinois, and a JD from Chicago-Kent College of Law, Illinois Institute of Technology.
Chief Technology Officer
Mr. Keller is responsible for all technology strategy and execution, including the vision and development of myLab™, Steep Hill’s proprietary ERP software solution. Mr. Keller joined Steep Hill from the publicly traded company, Amadeus, and applies over twenty years of professional experience in building software development teams, product development, Agile and Scrum methodologies, IT systems management, architecting scalable enterprise products, networking, embracing the cloud ecosystem, emerging technologies and setting strategic planning.
Reggie Gaudino, Ph.D.
Chief Science Officer
Dr. Gaudino oversees all scientific research and development for Steep Hill and manages the Ynsight™ genetics division. Dr. Gaudino directed a team of researchers which led to the development of GenKit™, the first cannabis DNA-based sex test. The research from Dr. Gaudino has been peer-reviewed and published, leading to important new discoveries in the cannabis industry. He is internationally recognized as a leader in the field of cannabis genetics where his former experience as a Patent Agent with Sequenome brings valuable insight to the cannabis industry.
Chief Global Expansion Officer
Mr. Cathcart is the architect and leader of the company’s global expansion program, and responsible for the design, implementation, negotiation and management of Steep Hill’s licensee and joint ventures across the United States and around the world. Under Mr. Cathcart’s direction, Steep Hill has grown from one lab in Oakland, CA to labs in (10) U.S. states, D.C., Canada, Mexico, Israel and Jamaica. Mr. Cathcart has served as a C-suite executive and managed major brands such as Gillette and Nestlé at ad agencies Ogilvy & Mather and J. Walter Thompson.
Steve Kain, Ph.D., MBA
Chief Marketing Officer
Dr. Kain’s mission is to implement better solutions for Steep Hills’ various stakeholders. He also provides leadership in marketing and the development of innovative software, products and services that enable our customers, licensees and strategic partners to excel in the global cannabis industry. Prior to joining Steep Hill, Dr. Kain gained extensive commercial experience in genomics, cell biology, drug discovery, and DNA sequencing at leading companies such as Thermo Fisher Scientific, NuGEN Technologies, Complete Genomics and Agilent Technologies.
Chief Financial Officer
Mr. Cowart develops, monitors and evaluates overall corporate financial strategy with an emphasis on long-term financial and operational planning, capital requirements, and enhancing shareholder value. Prior to joining Steep Hill, Mr. Cowart had twenty years of experience in corporate M&A and fund-raising activities including cofounding a publicly-traded European satellite communications provider which grew to over $200 million in revenue in just 5 years. He has served as a financial consultant to numerous venture-backed companies in the San Francisco Bay Area.
Chief Revenue Officer
Mr. Daniel leads multiple teams that encompass National Sales, Customer Experience, Cultivation Science and Steep Hill Express™. Prior to joining Steep Hill, Mr. Daniel worked in various management roles in the film industry, before spending 14 years as a non-profit development executive, overseeing more than $63 million in fundraising. He co-founded two social purpose companies, Make a Stand, Inc. and STAND Technologies. A long-time activist for cannabis legalization, his passion for social causes and social responsibility inspired his transition to Steep Hill.